Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal |
| |
| Authors: | K.‐H. LIESENFELD T. LEHR C. DANSIRIKUL P. A. REILLY S. J. CONNOLLY M. D. EZEKOWITZ S. YUSUF L. WALLENTIN S. HAERTTER A. STAAB |
| |
| Affiliation: | 1. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany;2. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA;3. Population Health Research Institute, McMaster University, Hamilton, ON, Canada;4. Lankenau Institute for Medical Research and the Heart Center, Wynnewood, PA, USA;5. Department of Medical Sciences, Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden |
| |
| Abstract: | See also Liesenfled K‐H, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, EzekowitzMD, Yusuf S,Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial. J Thromb Haemost 2011; 9: 2168–75; and Patel JP, Green B, Patel RK, Davies JG, Arya R. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: a rebuttal. This issue, pp 500–2. |
| |
| Keywords: | |
|
|
